The Marketing Claims That Trigger FDA Warning Letters for Clinics (and How to Check Your Own Copy)

Which marketing claims actually get a clinic an FDA Warning Letter or an FTC order? Almost always the same handful: language that says a product cures or treats a disease, promises a guaranteed outcome, claims something is completely safe, says “clinically proven” without a study behind it, or calls a compounded or unapproved product “FDA-approved.” None of these require bad intent. A clinic copies a phrase from a supplier’s website, a copywriter reaches for a stronger verb, and a service page now makes a claim the practice cannot substantiate. This guide walks through the exact categories regulators flag, with the safer way to say each one, and shows you how to run your own copy against the same patterns for free.

TL;DR

• Two regulators, two angles. The FDA polices whether your claims turn a product into an unapproved “drug” under the Food, Drug, and Cosmetic Act. The FTC polices whether your claims are substantiated and not deceptive under the FTC Act. A single sentence can draw both.
• The triggers are predictable. Cure and disease-treatment claims, absolute-safety language (“100% safe,” “no side effects”), outcome guarantees, unsubstantiated efficacy (“clinically proven” with no citation), off-label and compounded-drug promotion, “FDA-approved” misuse, and unsupported comparisons account for the large majority of enforcement.
• The standard is specific. The FTC expects “competent and reliable scientific evidence,” and for a health claim that usually means well-conducted human studies, not a mechanism story or a testimonial [1].
• You can check your own copy. Our free Claim Checker scans pasted copy against the same FDA Warning Letter and FTC patterns, with the regulator precedent shown next to every flag. Nothing leaves your browser.
• A scan is not a clearance. Screening tools and this guide are educational. Your clinic’s own licensed physician and your counsel remain the final gate on any substantive medical claim.

If you run a physician-led practice, you did not get into medicine to parse the difference between a structure-function claim and a disease claim. The trouble is that this distinction, and a few others like it, decides whether your service page is ordinary marketing or an unapproved drug claim in the eyes of the FDA. The good news is that the lines are well documented and the risky phrases are a short, learnable list. Here is the list, what each one signals to a regulator, and how to say the same thing safely.

FDA vs FTC: who polices what

Two federal agencies sit over health marketing, and they ask different questions.

The FDA cares about what your product is. Under the Federal Food, Drug, and Cosmetic Act, a product becomes a “drug” the moment it is marketed to diagnose, cure, mitigate, treat, or prevent a disease [2]. A supplement, peptide, IV drip, or compounded preparation sold with disease-treatment language is, by that definition, an unapproved new drug, and the agency’s standard response is a Warning Letter quoting your own marketing back to you [3].

The FTC cares about whether your claims are true and substantiated. Under Section 5 of the FTC Act, an advertising claim that is likely to mislead a reasonable consumer, or that you cannot back with evidence, is a deceptive act [4]. The FTC’s 2022 Health Products Compliance Guidance sets the bar: health claims need “competent and reliable scientific evidence,” which for most efficacy claims means randomized, controlled human trials, not animal data, not a single study, and not a plausible biological mechanism [1].

A practical way to hold it: the FDA asks “did your claim turn this into a drug?” and the FTC asks “can you prove what you said?” One sentence on a service page can fail both tests at once.

The claim categories regulators flag

Across the FDA Warning Letters and FTC orders we track in the FDA / FTC Atlas, the same categories recur. Here is each one, why it draws enforcement, and the safer alternative.

Claim category	Why it triggers	A safer way to say it
Cure / disease-treatment	Turns the product into an unapproved drug under the FD&C Act	Describe the symptom addressed and cite the evidence; avoid disease verbs
Absolute safety	No medical treatment is risk-free; a known false statement	State the actual adverse-event profile from the labeling
Outcome guarantee	Presumptively deceptive; outcomes vary by patient	Share documented results with context, not a promise
Unsubstantiated efficacy	”Clinically proven” with no study fails the evidence bar	Cite the specific study, or soften to what the evidence supports
Off-label / compounded promotion	Markets an unapproved use or product as routine	Disclose regulatory status and the clinical context
”FDA-approved” misuse	Compounded and most supplements are not FDA-approved	State the true status; never imply approval you do not have
Unsupported comparison	Equivalence to a brand drug needs bioequivalence data	Describe what your preparation contains, without the comparison

Cure and disease-treatment claims

This is the single most common trigger. Words like cure, cures, reverse, eliminate, or treats [named disease] tell the FDA your product is intended to treat disease. “Reverses type 2 diabetes,” “cures low T,” “eliminates anxiety” are all disease claims. The fix is not to go silent; it is to describe what the therapy actually does for a symptom, with evidence, and to let your physician decide what is defensible.

Absolute-safety language

“100% safe,” “completely safe,” “no side effects,” and “side-effect free” are flagged almost on sight, because no drug or procedure is free of risk and the agencies have said so repeatedly. The honest and safer version states the real adverse-event profile from the relevant labeling or trial data.

Outcome guarantees

“Guaranteed results,” “guaranteed to work,” and money-back-framed promises of a clinical outcome are presumptively deceptive under FTC Section 5, because clinical outcomes vary by patient [1][4]. Documented results, presented with context, are persuasive and defensible. A guarantee is neither.

Unsubstantiated efficacy

“Clinically proven,” “scientifically proven,” and “doctor recommended” imply a body of evidence. If that evidence is not real, specific, and human, the claim fails the FTC’s substantiation standard [1]. If you have the study, cite it. If you do not, say what the evidence actually supports.

Off-label and compounded-drug promotion

Marketing a compounded drug, a research peptide, or an off-label use as a routine offering invites both agencies. Compounded GLP-1 medications were the subject of an FDA Warning Letter cluster, and research peptides like BPC-157 carry their own warnings. The defensible approach discloses the regulatory status plainly and frames the clinical context, rather than presenting an unapproved product as ordinary.

”FDA-approved” misuse

Compounded drugs are not FDA-approved. Dietary supplements are not FDA-approved. Calling either “FDA-approved,” or implying it, is a distinct and serious trigger. State the true status. If a specific ingredient or device has a genuine clearance, describe exactly that, and nothing broader.

Unsupported comparisons

“Same as Ozempic,” “identical to the brand,” and similar equivalence claims for a compounded preparation require bioequivalence data that almost no clinic has. Describe what your preparation contains and how it is used, without the comparison.

Vertical-specific landmines

Some triggers are specific to a service line. These are the patterns we see most often in each, and each links to the real enforcement record in the Atlas.

• TRT and hormones (Atlas): “Low T” used as a diagnosis, and any claim that testosterone reverses or cures a condition. The FDA’s own labeling changes have flagged hormone-cure language directly.
• GLP-1 and weight loss (Atlas): compounded-semaglutide marketing without status disclosure, and “same as Wegovy” equivalence claims.
• Peptides (Atlas): naming research peptides without disclosing that they are not FDA-approved for the use described.
• Stem cell and regenerative (Atlas): marketing exosome, PRP, or stem cell products to treat named diseases. This is one of the FDA’s most active clinic-enforcement areas, because most of these products are unapproved biologics [5].
• Medical spas (Atlas): “permanent,” “risk-free,” or “no downtime” claims for neurotoxins and fillers, and marketing imported or non-US-approved injectables.
• Compounding pharmacies (Atlas): “FDA-approved compounded” language, and brand-equivalence claims, both of which the agencies treat as deceptive [6].

How to check your own copy

You do not have to read every Warning Letter to find your own exposure. Three steps:

1. Run the copy through the Claim Checker. Paste any page, ad, or email, and it scans against the same FDA and FTC patterns described above, with the regulator precedent shown next to each flag. It is free, requires no email, and the text never leaves your browser.
2. Read the matching Atlas entries. When a flag fires, the precedent next to it links to the real letter or order. Seeing how a regulator described the same phrasing in an enforcement action is the fastest way to understand why it matters.
3. Send the flagged language to your physician and, where warranted, your counsel. This is the step a tool cannot do for you, and it is the one that matters most.

What a scan does not replace

A clean scan is not a regulatory clearance, and this article is not legal advice. The Claim Checker catches the most common, well-documented enforcement triggers, which is most of the practical risk, but it is a screening tool. The questions that decide real compliance, whether a specific claim is substantiated for your specific patient population, whether a therapy is appropriately framed for your scope, are clinical and legal judgments. They belong to your clinic’s own licensed physician and your counsel. The goal of screening is to surface the obvious problems early and cheaply, so the expensive human review is spent on the claims that genuinely need it.

That division of labor is the whole point. Catch the copied “100% safe” and the stray “cures” with a tool in seconds. Spend your physician’s time on the judgment calls. Ship marketing that sounds like the practice you actually run.

Frequently asked questions

What is the difference between an FDA and an FTC issue in my marketing?

The FDA cares whether your claims turn a product into an unapproved drug. Under the Food, Drug, and Cosmetic Act, marketing a product to diagnose, cure, mitigate, treat, or prevent a disease makes it a drug, and an unapproved one draws a Warning Letter [2][3]. The FTC cares whether your claims are substantiated and not deceptive under Section 5 of the FTC Act, and its standard for health claims is competent and reliable scientific evidence [1][4]. A single claim can implicate both agencies at once.

Does “clinically proven” really get clinics in trouble?

It can, when there is no study to back it. “Clinically proven” and “scientifically proven” assert a body of human evidence. If that evidence is not real, specific, and clinical, the claim fails the FTC’s substantiation standard [1]. If you have the study, cite it directly so a reader and a regulator can verify it. If you do not, describe what the evidence actually supports instead.

Are dietary supplements and compounded drugs FDA-approved?

No. Dietary supplements are not FDA-approved, and compounded drugs are not FDA-approved. Calling either “FDA-approved,” or implying approval you do not have, is a distinct enforcement trigger. If a specific ingredient, device, or branded drug has a genuine clearance, describe exactly that and nothing broader [6].

Is the Claim Checker a substitute for legal or compliance review?

No. The Claim Checker flags the most common documented FDA and FTC triggers and shows the precedent behind each one, which catches most everyday risk quickly. But a clean scan is not a regulatory clearance. Whether a specific claim is substantiated and appropriate for your practice is a clinical and legal judgment that belongs to your own physician and counsel.

Why do clinics get flagged when they did not intend to deceive anyone?

Because intent is not the test. The FDA’s drug definition turns on how a product is marketed, not on whether the marketer meant to mislead, and the FTC’s deception standard turns on whether a claim is likely to mislead a reasonable consumer and whether it is substantiated [2][4]. Most flagged language is copied from a supplier, inherited from an old site, or written by someone reaching for a stronger verb. The phrasing is what gets cited, regardless of intent, which is exactly why a fast screen of the actual words is worth doing.

Citations

1. Federal Trade Commission. Health Products Compliance Guidance. December 2022. ftc.gov/business-guidance/resources/health-products-compliance-guidance. Accessed June 8, 2026.
2. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, Section 201(g) (definition of “drug”). fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act. Accessed June 8, 2026.
3. U.S. Food and Drug Administration. Warning Letters. fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters. Accessed June 8, 2026.
4. Federal Trade Commission. A Brief Overview of the Federal Trade Commission’s Investigative, Law Enforcement, and Rulemaking Authority (Section 5, deceptive acts or practices). ftc.gov/about-ftc/mission/enforcement-authority. Accessed June 8, 2026.
5. U.S. Food and Drug Administration. FDA Warns About Stem Cell Therapies. fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies. Accessed June 8, 2026.
6. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers. Accessed June 8, 2026.